Ask AI
ProCE Banner Activity

Are You Prepared? New Central Role of Radiology in AD Diagnosis, Safety Monitoring, and Response Assessment

Slideset

Advances in Alzheimer's disease diagnostics and disease-modifying therapies have expanded the role of neuroimaging throughout the patient care pathway. These downloadable slides explore how PET and MRI inform diagnosis, treatment eligibility, and ongoing management. Through clinical case exploration, learners will examine imaging interpretation, overlapping pathologies, treatment-related safety concerns, and approaches to evaluating therapeutic response.

Released: October 22, 2026

Continue Activity

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Target Audience

This activity is intended for HCPs practicing in the United States who care for people at risk for or already diagnosed with AD, including primary care and family medicine providers, radiologists and nuclear medicine specialists, NPs, PAs, pharmacists, neurologists, and geriatricians.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Identify the clinical scenarios in which MRI, amyloid PET, tau PET, and FDG-PET are ordered for patients with cognitive symptoms

  • Interpret key findings in MRI and PET reports and how they affect diagnosis and treatment eligibility

  • Coordinate imaging with blood biomarkers and specialist referral across the Alzheimer's disease care pathway

  • Recognize ARIA and other imaging findings that change the risk-benefit discussion for anti-amyloid therapy

Additional Disclosures

Generative artificial intelligence (AI) tools were used for revising or refining educational content. All AI-assisted content underwent human review, editing, and validation by qualified faculty and accredited education staff to ensure scientific accuracy, balance, and compliance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education.